Literature DB >> 16445838

Myeloid lineage-selective growth of revertant cells in Fanconi anaemia.

Satoshi Hamanoue1, Hiroshi Yagasaki, Toshihisa Tsuruta, Tsukasa Oda, Hiromasa Yabe, Miharu Yabe, Takayuki Yamashita.   

Abstract

Fanconi anaemia (FA) is a genetically heterogeneous chromosome instability syndrome characterised by bone marrow failure and congenital anomalies. Although an increasing number of reports suggest that reversion mosaicism noted in peripheral blood lymphocytes (PBLs) is associated with mild haematopoietic failure in FA, myeloid cells are rarely directly examined. We here report a patient with prolonged mild pancytopenia in whom proliferation of revertant cells was detected in mature myeloid cells but not in PBLs. While this patient had inherited heterozygous mutations, 2546delC and 3720-3724del, in the major FA gene FANCA, Epstein-Barr virus-immortalised lymphoblastoid cells from the patient had 2546C > T instead of 2546delC, resulting in expression of a functional missense protein. As the identical reversion was detected in polymorphonuclear granulocytes and mononuclear phagocytes, sustained haematopoiesis in the patient can be attributed to a selective growth advantage of revertant myeloid cells. It is noteworthy that such a myeloid lineage-selective mosaicism is overlooked in routine examination of PBLs. Recognition of this status will expand the role of reversion mosaicism in the pathophysiology of FA.

Entities:  

Mesh:

Year:  2006        PMID: 16445838     DOI: 10.1111/j.1365-2141.2005.05916.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

Review 1.  Revertant mosaicism in skin: natural gene therapy.

Authors:  Joey E Lai-Cheong; John A McGrath; Jouni Uitto
Journal:  Trends Mol Med       Date:  2010-12-29       Impact factor: 11.951

2.  Radiologic differences between bone marrow stromal and hematopoietic progenitor cell lines from Fanconi Anemia (Fancd2(-/-)) mice.

Authors:  Hebist Berhane; Michael W Epperly; Julie Goff; Ronny Kalash; Shaonan Cao; Darcy Franicola; Xichen Zhang; Donna Shields; Frank Houghton; Hong Wang; Peter Wipf; Kalindi Parmar; Joel S Greenberger
Journal:  Radiat Res       Date:  2014-01-07       Impact factor: 2.841

Review 3.  Ethical considerations in genomic testing for hematologic disorders.

Authors:  Jonathan M Marron; Steven Joffe
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

4.  Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.

Authors:  K Twaroski; C Eide; M J Riddle; L Xia; C J Lees; W Chen; W Mathews; D R Keene; J A McGrath; J Tolar
Journal:  Br J Dermatol       Date:  2019-07-08       Impact factor: 9.302

5.  Self-reverting mutations partially correct the blood phenotype in a Diamond Blackfan anemia patient.

Authors:  Parvathy Venugopal; Sarah Moore; David M Lawrence; Amee J George; Ross D Hannan; Sarah Ce Bray; Luen Bik To; Richard J D'Andrea; Jinghua Feng; Amanda Tirimacco; Alexandra L Yeoman; Chun Chun Young; Miriam Fine; Andreas W Schreiber; Christopher N Hahn; Christopher Barnett; Ben Saxon; Hamish S Scott
Journal:  Haematologica       Date:  2017-09-29       Impact factor: 9.941

Review 6.  Clonal hematopoiesis and bone marrow failure syndromes.

Authors:  Sergiu Pasca; Lukasz P Gondek
Journal:  Best Pract Res Clin Haematol       Date:  2021-05-25       Impact factor: 3.670

7.  Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3.

Authors:  Anna M G Pasmooij; Hendri H Pas; Maria C Bolling; Marcel F Jonkman
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.

Authors:  Wataru Sakai; Elizabeth M Swisher; Beth Y Karlan; Mukesh K Agarwal; Jake Higgins; Cynthia Friedman; Emily Villegas; Céline Jacquemont; Daniel J Farrugia; Fergus J Couch; Nicole Urban; Toshiyasu Taniguchi
Journal:  Nature       Date:  2008-02-10       Impact factor: 49.962

Review 9.  Secondary mutations of BRCA1/2 and drug resistance.

Authors:  Kiranjit K Dhillon; Elizabeth M Swisher; Toshiyasu Taniguchi
Journal:  Cancer Sci       Date:  2011-01-30       Impact factor: 6.716

Review 10.  Clonal hematopoiesis in the inherited bone marrow failure syndromes.

Authors:  Frederick D Tsai; R Coleman Lindsley
Journal:  Blood       Date:  2020-10-01       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.